# Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

> **NCT04944914** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 188 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** camrelizumab
- **RADIATION:** stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT04944914
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 188 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04944914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04944914, "Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04944914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*